4 results about "Pyridine sulfonamide" patented technology

Use of a pyridine sulfonamide phosphate compound or a pharmaceutical composition comprising the same in the preparation of a drug for treating pulmonary edema. This drug inhibits the NKCC1 target in the lungs through a novel mechanism of action, demonstrating outstanding efficacy in treating pulmonary edema with high safety. It can significantly reduce drug distribution in kidney tissue, thereby reducing adverse effects such as electrolyte disturbances caused by potent diuretics. It holds promise as a novel drug for the clinical treatment of pulmonary edema and has a very broad clinical application prospect.

A nasal spray composition for treating cerebral edema comprises a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof. The nasal spray of the present application has the advantages of high brain penetration, strong efficacy, few side effects, good patient compliance, convenient carrying and use, etc., significantly improving the effectiveness and safety of the drug. In addition, the nasal spray composition of the present application also contains a stabilizer, rhamnose. As a stabilizer, rhamnose can greatly improve the stability of the nasal spray composition.

The application provides a pyridine-3-sulfonamide compound and an application thereof. The pyridine-3-sulfonamide compound provided by the application is a novel structure inhibitor of bacterial type II fatty acid synthesis dehydrogenase FabX, has a bacteriostatic effect on Helicobacter pylori strains, and can be further made into an anti-Helicobacter pylori drug or used for treating or preventing diseases caused by Helicobacter pylori infection.

An inhalation preparation for treating pulmonary edema, comprising a pyridine sulfonamide phosphate compound represented by formula 1 or a pharmaceutically acceptable salt thereof and a cationic guar gum. The cationic guar gum can greatly improve the permeability of the pyridine sulfonamide phosphate compound or the pharmaceutically acceptable salt thereof in a Calu-3 cell model (an in vitro simulation of lung tissue epithelial cell model). The application also provides a preparation method of the inhalation preparation: under normal temperature and pressure, the main drug, the absorption promoter and the freeze-drying excipient are dissolved in water in proportion and are constant volume to the total amount, and are filtered and freeze-dried. The inhalation preparation prepared by the application has strong lung permeability, simple production process and good application prospect.